TABLE 1

Demographics and Clinical Descriptors of Study Patients and Associations With Treatment Failure

Total Sample, n = 172No Treatment Failure, n = 156Treatment Failure, n = 16Pa
Age, median (IQR), d39.5 (29.5–63.5)44.144.6.93
Female57 (33.1)54 (34.6)3 (18.8).20
Race/ethnicity.61
 Caucasian107 (62.2)93 (59.6)14 (87.5)
 Hispanic44 (25.6)42 (26.9)2 (12.5)
 Other8 (4.7)8 (5.1)0
 Unknown8 (4.7)8 (5.10
 Asian3 (1.7)3 (1.9)0
 Black2 (1.2)2 (1.3)0
Payer type.01
 No insurance8 (4.7)8 (5.1)0
 Medicaid88 (51.2)85 (54.5)3 (18.8)
 Private/commercial76 (44.2)63 (40.4)13 (81.3)
Admittedb89 (51.7)81 (51.9)8 (50).88
Median LOS if admitted (IQR), h41 (26–61.5)45.043.6.91
Encounter at Primary Children’s Hospitalc106 (61.6)94 (60.3)12 (75).25
Feverd29 (16.9)28 (18.4)1 (6.3).22
Previous antibiotics29 (16.9)24 (15.8)5 (31.3).12
Encounter antibiotics97 (56.4)89 (57.1)8 (50).59
Anti-MRSA encounter antibioticse46 (26.7)43 (48.3)3 (37.5).56
Discharge antibiotics150 (87.2)135 (86.5)15 (93.8).41
Incision and drainage performed66 (38.4)58 (37.2)8 (50).36
Location.03
Perianal72 (41.9)61 (39.6)11 (68.8)
Head38 (22.1)38 (24.7)0
Extremity34 (19.8)32 (20.8)2 (12.5)
Trunk26 (15.1)23 (14.9)3 (18.8)
  • Values are expressed as number (column percentage) unless otherwise indicated. IQR, interquartile range; LOS, length of stay.

  • a Comparison of no treatment failure with treatment failure.

  • b Patients may have been admitted to observation, inpatient, or same-day surgery settings. This group is compared with patients discharged to home from an ED encounter.

  • c Primary Children’s Hospital is the tertiary children’s hospital of Intermountain Healthcare. Encounters at Primary Children’s Hospital were compared with encounters at 21 other community or regional hospitals in the Intermountain Healthcare network.

  • d Fever status unknown for 4 patients.

  • e The anti-MRSA category included trimethoprim/sulfamethoxazole, clindamycin, vancomycin, or linezolid.